Loading stock data…
Artivion (AORT)
$23.15-0.46 (-1.95%)
Market OpenUpdated 2:07 PM EDT
Artivion, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artivion, Inc. in the Healthcare sector is trading at $23.15 with a market capitalization of $1.1B. Wall Street consensus targets $42.00 (8 analysts), implying a +81.4% move over the next 12 months. The stock is currently near its 52-week low of $19.16, remaining 38.6% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +81.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $116.34M↑ | $115.99M↑ | $113.39M↑ | $112.97M↑ | $98.98M |
| Gross Profit | $75.45M↑ | $73.14M↓ | $74.39M↑ | $73.11M↑ | $63.58M |
| Operating Income | $5.79M↓ | $7.18M↓ | $9.04M↑ | $8.38M↑ | $2.15M |
| Net Income | $1.42M↓ | $2.43M↓ | $6.50M↑ | $1.34M↑ | -$505,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.06B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.60%
Volume
Today's trading volume
481,420
Recent News
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
1 of Wall Street’s Favorite Stocks with Solid Fundamentals and 2 We Question
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
What Artivion (AORT)'s Strong Q1 Growth But Lowered Guidance Means For Shareholders
In its recent Q1 2026 update, Artivion reported 17.5% year-over-year revenue growth to US$116.3 million, with solid contributions from stent grafts, On-X heart valves, preservation services, and BioGlue, but missed analysts’ EPS estimates and slightly reduced full-year revenue guidance. This combination of robust product-line momentum and a guidance cut highlights the tension between Artivion’s growth ambitions and the profitability and execution challenges it currently faces. We’ll now...
Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Artivion (NYSE:AORT) and its peers.
3 High-Flying Stocks Walking a Fine Line
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.